Diabetes

September 7, 2017
Published by admin_auro at September 7, 2017
Categories

Natural product therapy for middle aged TIIDM patients: Artesunate, isolated from Artemisia Annua L, decreases DNA-PPK expression, suppresses phosphorylation of HSP90a, increases AMPK activity, augments mitochondrial biogenesis and energy metabolism, promotes weight loss and exercise endurance and alleviates TIIDM via down regulation of its target gene, 8/September/2017, 1.08 am

Introduction: What they say A study from the Laboratory of Obesity and Aging Research, National Heart Lung and Blood Institute, National Institutes of Health, Bethesda, MD […]
Do you like it?0
Read more
September 7, 2017
Published by admin_auro at September 7, 2017
Categories

Molecular therapy for TIIDM and obesity-associated metabolic deficits: Rivaroxaban (Trade name: Xarelto), an anti-coagulant and a blood thinner,  increases Lipocalin 2 (LCN2) expression, activates an MC4R-dependent anorexigenic pathway, suppresses appetite and weight gain, increases insulin secretion, improves glucose tolerance, promotes glucose homeostasis, improves obesity-associated metabolic deficits and prevents progression to TIIDM via down regulation of its target gene, 8/September/2017, 12.32 pm

Introduction: What they say A study from the Department of Physiology-Cellular Biophysics, College of Physicians and Surgeons, Columbia University, New York, New York, USA shows that […]
Do you like it?0
Read more
September 1, 2017
Published by admin_auro at September 1, 2017
Categories

Molecular therapy for Metabolic diseases: Rivaroxaban (Trade name: Xarelto), an anticoagulant drug, increases the expression of Caveolin-1, stabilizes insulin receptor, promotes insulin sensitivity, increases vasorelaxation, and decreases the risk of hyperglycemia and TIIDM via up regulation of its target gene., 1/September/2017, 11.51 pm

Introduction: What they say A study from the Institute for Molecular Systems Biology, ETH Zurich, Zurich, Switzerland shows that “MicroRNAs 103 and 107 regulate insulin sensitivity.” […]
Do you like it?0
Read more
September 1, 2017
Published by admin_auro at September 1, 2017
Categories

Molecular therapy for TIIDM and obesity-associated metabolic deficits: Ruxolitinib, a drug used in the treatment of Myelofibrosis,  increases Lipocalin 2 (LCN2) expression, activates an MC4R-dependent anorexigenic pathway, suppresses appetite and weight gain, increases insulin secretion, improves glucose tolerance, promotes glucose homeostasis, improves obesity-associated metabolic deficits and prevents progression to TIIDM via down regulation of its target gene, 1/September/2017, 11.28 pm

Introduction: What they say A study from the Department of Physiology-Cellular Biophysics, College of Physicians and Surgeons, Columbia University, New York, New York, USA shows that […]
Do you like it?0
Read more
Prev page
123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113
Next page